• Asia’s leading and most highly-anticipated event
  •  Highlights on market access and commercialization case study
  •   The region’s largest gathering of leading and future stakeholders across the value chain

With continued growth and evolving market dynamics, sales of global biosimilars is forecasted to reach $25 billion in the year of 2020 and Asia is expected to ride on the uphill trend. Biosimilar regulations are expected to change and having the right commercialization strategy will be the key to accessing new markets.

At IBC’s Biosimilars Asia Conference, top industry players will explore practical strategies for gaining access to emerging markets, clarifying regulatory pathways and clinical approvals, evaluating business models, risks and investment opportunities, pricing and commercialization strategies and successful case studies.

Why you should attend

  • Gain in-depth content from leading biosimilars companies and case studies on market access and commercialization strategies
  • Understand the latest development in regulations and Government pricing plans in China, EU, US, Korea and India, how to access these markets and gain approvals
  • Insights on key success factors for entering the biosimilars investment space with different business models as well as developing win-win partnerships  
  • Learn innovative and cost effective approaches in biosimilars production and development
  • Gather the latest market intelligence and analysis and identify new trends and opportunities in Biosimilars R&D, contract manufacturing and commercialization in Asia

View full agenda »

凭借其自身的持续性增长以及不断变化的市场动态,预计全球生物仿制药的销售额可在2020年达到250亿美元,而亚洲则有望从这波上升趋势中受益。生物仿制药法规可能会有所变化,因此拥有正确的商业化战略将是打入新市场的关键。

在 IBC主办的亚洲生物仿制药会议上,领先的业内人士将探索实用策略,以进入新兴市场,明确监管途径和临床审批,评估商业模式、风险和投资机会,定价和商业化战略以及成功案例。

您为何要参加

  • 从领先的生物仿制药公司和案例研究中获取有关市场准入和商业化战略的深度内容
  • 了解中国、欧盟、美国、韩国和印度在法规及政府定价计划方面的最新发展,如何进入这些市场及获得批准
  • 有关利用不同商业模式进入生物仿制药投资领域的关键成果要素以及开发双赢合作伙伴关系的洞见  
  • 学习在生物仿制药生产和开发方面具有成本效益的创新方法
  • 收集最新的市场情报,并分析和确定在亚洲生物仿制药研发、合同制造和商业化方面的新趋势和机会

 

更多详情,请致电 +65 65082491 或发送电子邮件至Sophia.zhao@ibcasia.com.sg与Sophia Zhao联系

议程 »

 

2015 Speakers

Dr Ira Allen Jacobs
Oncology Portfolio Global Medical Lead-Biosimilars, Pfizer, US

Huiguo (Forrest) Hu
General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co., Ltd, China

Paul Thomas
Business Unit Head – Biosimilars, Biocon, India

Dr Shin Jae Chang
Vice President, Celltrion, Korea

Raj Kannan
Vice President, Commercial Head, Biosimilars, Merck, Switzerland

Dr. Martina A. Sersch
Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead, Genentech, Inc. / F. Hoffmann-La Roche Ltd.

View all speakers »

 

About the Biopharma Development & Production Week

The Biopharma Development & Production Week is the leading industry platform for pharma, biotech, CMOs, CROs, research institutes, investors and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia.  For more information visit www.biopharmaproduction.com

3 Conferences in 1 Location

 

 

Produced by2015 Supporting Association2015 Gold Sponsor 

 
2015 Silver Sponsors 2015 Session Spotlight Sponsor  
 
2015 Exhibitors   
 
2015 Media Partners   
IBC